Translational Session
Abnormalities in Calcium and Phosphorus in Malignancy: Mechanisms and Management Options
October 24, 2024 | 10:30 AM - 12:30 PM
Location: Room 7, Convention Center
Session Description
Hypercalcemia commonly occurs in people with malignancy. Direct bone invasion (primary bone cancer, bone metastasis, multiple myeloma) and humoral hypercalcemia (elevated PTH, PTH-related peptide, and calcitriol) are the predominant etiologies. Hypophosphatemia is a common complication of cancer therapy. Appropriate diagnosis and timely management of these abnormalities are critical to patient outcomes. This session updates participants on the prevalence of these disorders, discusses mechanisms and contributing factors, and assesses treatment options in the modern era.
Learning Objective(s)
- Recall incidence and prevalence of hypercalcemia and hypophosphatemia in malignancy
- Characterize mechanisms of hypercalcemia and hypophosphatemia in malignancy
- Describe approaches to management of hypercalcemia of malignancy
- Identify the high fracture risk intrinsic to malignancy and explain its treatment
- Discuss the etiologies and management of hypophosphatemia in malignancy
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
- Onconephrology
Moderators
Presentations
- Malignancy-Associated Hypercalcemia: Prevalence, Impact, and Management
10:30 AM - 11:00 AM
- Humoral Hypercalcemia of Malignancy
11:00 AM - 11:30 AM
- Hypophosphatemia in Cancer Therapy: Prevalence, Mechanisms, and Complications
11:30 AM - 12:00 PM
- Bad to the Bone: Effect of Modern Cancer Therapeutics on Bone Health
12:00 PM - 12:30 PM